New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 11, 2012
10:21 EDTSWN, LIFE, HMY, BMY, RRC, IPI, GFI, AU, YELP, QEP, IPCI, COGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AngloGold (AU) initiated with an Outperform at Credit Suisse... Bristol-Myers (BMY) reinstated with a Neutral at Credit Suisse... Cabot Oil & Gas (COG) initiated with an Outperform at Bernstein... Gold Fields (GFI) initiated with a Neutral at Credit Suisse... Harmony Gold (HMY) initiated with an Underperform at Credit Suisse... Intellipharmaceutics (IPCI) initiated with a Buy at Brean Murray... Intrepid Potash (IPI) initiated with a Buy at Wunderlich... Life Technologies (LIFE) initiated with a Buy at WallachBeth... QEP Resources (QEP) initiated with an Outperform at BMO Capital... Range Resources (RRC) initiated with an Outperform at Bernstein... Southwestern Energy (SWN) initiated with an Outperform at Bernstein... Yelp (YELP) initiated with a Neutral at Piper Jaffray.
News For AU;BMY;COG;GFI;HMY;IPCI;IPI;LIFE;QEP;RRC;SWN;YELP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 18, 2014
08:03 EDTQEPQEP Resources downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded QEP Resources and others in the Exploration & Production space to Market Perform on concern that access to capital will become much more difficult amid low oil prices.
06:48 EDTAUAngloGold initiated with a Sector Perform at RBC Capital
Subscribe for More Information
December 17, 2014
13:21 EDTSWNNew York to officially ban fracking, NY Times reports
New York Governor Andrew Cuomo announced his administration will block hydraulic fracturing, or fracking, for natural gas in the state when an existing five-year moratorium pushed by the state Department of Environmental Conservation ends next year, reported The New York Times. The Marcellus shale formation spans New York, parts of Pennsylvania, eastern Ohio, western Maryland, most of West Virginia and into extreme western Virginia. Companies with operations in the Marcellus shale include Warren Resources (WRES), Southwestern Energy (SWN) and Talisman Energy (TLM). Reference Link
December 16, 2014
09:59 EDTRRCOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:19 EDTRRCRange Resources upgraded to Outperform from Sector Perform at Howard Weil
Subscribe for More Information
08:47 EDTBMYHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
05:24 EDTRRCRange Resources upgraded to Equal Weight from Underweight at Barclays
Subscribe for More Information
December 15, 2014
06:14 EDTRRCRange Resources reports Utica/Point Pleasant well results
Subscribe for More Information
December 11, 2014
08:16 EDTIPIBHP sees potash as focus for growth in China, WSJ reports
Mining giant BHP Billiton said it is focusing on potash as an area of strategic growth in China, with Mike Henry, a president for BHP saying potash "can be our fifth pillar,” adding to the four key markets of iron ore, oil and natural gas, copper and coal that the company had identified previously, reported The Wall Street Journal. Other publicly traded companies in the potash space include Agrium (AGU), Intrepid Potash (IPI), Mosaic (MOS), Potash (POT). Reference Link
December 10, 2014
12:04 EDTIPIUSDA lowers 2014/15 soybean ending stock forecast
Subscribe for More Information
12:00 EDTSWNStocks with call strike movement; SWN ESV
Southwestern Energy (SWN) March 34 call option implied volatility increased 4% to 46, Ensco (ESV) June 34 call option implied volatility increased 3% to 47 according to IVolatility.
08:01 EDTRRCCapital One to hold a conference
Subscribe for More Information
06:08 EDTBMYBristol-Myers partners with Ono Pharma and Kyowa Hakko Kirin for oncology trial
Subscribe for More Information
December 9, 2014
16:35 EDTBMYBristol-Myers raises dividend to 37c per share from 36c per share
Subscribe for More Information
14:44 EDTYELPYelp management to meet with Piper Jaffray
Subscribe for More Information
08:25 EDTBMYBristol-Myers data positive, says BMO Capital
Subscribe for More Information
07:01 EDTCOGCabot Oil & Gas coverage resumed with a Hold at Stifel
Subscribe for More Information
06:11 EDTYELPYelp implied volatility of 44 at lower end of index mean range
Subscribe for More Information
December 8, 2014
13:32 EDTBMYPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
05:53 EDTBMYStocks with implied volatility movement; BSX BMY
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use